Although the prior gold standard of Sanger sequencing covers all EGFR mutations within exons 18–21, it’s analytic sensitivity (20–40% tumor cellularity) may not be adequate in the clinical diagnostic setting where specimens containing low tumor cellularity are not uncommon [7, 8]. This evidence concerns the gene EGFR and neoplasm.